OTC Derivatives Regulation


Corporate Finance | Capital Markets, Derivatives + Commodities, and Structured Products

New York, NY

David H. Kaufman

David H. Kaufman


On June 17th, the Obama Administration released its white paper, titled “Financial Regulatory Reform: A New Foundation,” which proposes fundamental reforms to the financial regulatory system, including reforms that would introduce far-reaching changes in the regulation of OTC derivatives. In the months since that announcement, Congress has heard testimony from industry participants and regulators and various new legislative proposals have been introduced. Industry organizations also have undertaken quite a number of measures intended to improve documentation and promote transparency. Although the new regulatory scheme is far from settled, the panel will discuss the changes that are likely to be implemented and the effects of those on the conduct of business in OTC derivatives and structured products.

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2019 Morrison & Foerster LLP. All rights reserved.